# US 2018/0021375 A1 · Modified blood clots > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2018/0021375 A1 - Document ID: US20180021375A1 - Status: Published application - Kind: A1 - Application number: 15/551,483 - Filed: 2016-02-16 - Published: 2018-01-25 - Earliest claimed: 2015-02-16 - Assignees: Nayacure Therapeutics Ltd. - Applicants: Nayacure Therapeutics Ltd. - Inventors: Shahar COHEN - Web page: https://patentgrep.com/patent/US20180021375A1 ## CPC - A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) - A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells - A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof} - A61L 27/3616: {Blood, e.g. platelet-rich plasma} - A61L 2400/04: Materials for stopping bleeding - A61L 2400/06: Flowable or injectable implant compositions - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract The present invention provides methods for preparing modified blood clots comprising removal of the cellular content of the blood clots. The invention further provides uses of the modified blood clots as therapeutic agents and as delivery vehicles for cells, bio-molecules and other agents. ## Claims ### Claim at position 1 1-46. (canceled) ### Claim 47 A method for preparing a modified blood clot comprising: (a) Obtaining a blood clot; and (b) Removing the cellular content of said blood clot; thereby obtaining a modified blood clot. ### Claim 48 (depends on 47) The method of claim 47, wherein said blood clot is formed in vivo at a site of bleeding. ### Claim 49 (depends on 47) The method of claim 47, wherein said blood clot is formed ex vivo from a blood sample or a blood product obtained from a donor. ### Claim 50 (depends on 49) The method of claim 49, wherein said blood sample is incubated in the absence of an anti-coagulation agent, or in the presence of at least one anticoagulant prior to clot formation. ### Claim 51 (depends on 50) The method of claim 50, wherein following the incubation with the anticoagulant at least one agent capable of reversing the action of the anticoagulant is added to the blood sample. ### Claim 52 (depends on 49) The method of claim 49, wherein the blood sample is further incubated in the presence of a coagulation activator. ### Claim 53 (depends on 47) The method of claim 47, wherein the method further comprises prior to step (a) a pre-modification step with a pre-modifying agent, wherein the pre-modifying agent is selected from a group consisting of a biomolecule, a drug, an antigen, a microbe, and a cell. ### Claim 54 (depends on 47) The method of claim 47, wherein the method further comprises a processing step (c) after step (b), wherein the processing step is selected from the group consisting of dehydration, lyophilization, cryopreservation, partial or complete digestion, purification, solubilization, fractionation, lysis and any combination thereof. ### Claim 55 (depends on 47) The method of claim 47, wherein the method further comprises after step (b) a step (c) of seeding cells or cell aggregates onto the modified blood clot, and optionally a further step (d) of eliminating the cells or cell aggregates from the modified blood clot, thereby changing at least one biological and/or mechanical property of the modified blood clot. ### Claim 56 A method of entrapping at least one agent within an insoluble biocompatible scaffold, said method comprising: (a) obtaining a blood clot; and (b) removing the cellular content of said blood clot; thereby obtaining a modified blood clot wherein said modified blood clot is characterized by being insoluble, biocompatible and comprising at least one agent entrapped therein. ### Claim 57 (depends on 47) A modified blood clot prepared according to the method of claim 47. ### Claim 58 A modified blood clot wherein said modified blood clot is modified ex vivo and is characterized by one or more of the following: (a) stabilized with anti-fibrinolytic factors, (b) free or substantially free of cellular content, (c) incorporates biomolecules with antimicrobial activity, (d) incorporates activated platelets and activated WBC-derived biomolecules, (e) incorporates platelets and WBC activating factors, and (f) incorporates soluble serum biomolecules such as albumin. ### Claim 59 (depends on 58) The modified blood clot of claim 58, wherein said modified blood clot is seeded ex vivo with cells or cell aggregates. ### Claim 60 (depends on 58) The modified blood clot of claim 58, wherein said seeded cells or cell aggregates are eliminated from the modified blood clot. ### Claim 61 (depends on 58) A pharmaceutical composition comprising the modified blood clot of claim 58 and a pharmaceutically acceptable carrier or excipient. ### Claim 62 (depends on 58) A method of treating a disease or medical condition, said method comprising the step of administering the modified blood clot of claim 58 to a subject in need thereof, wherein said disease or medical condition is selected from the group consisting of ischemic, degenerative, inflammatory, cancerous, genetic, traumatic, developmental or acquired medical condition or disease. ### Claim 63 (depends on 58) A method of drug delivery said method comprising the step of administering the modified blood clot of claim 58 into a subject in need thereof. ### Claim 64 (depends on 58) A method of changing cells, multi-cellular aggregates or tissues comprising a step of exposing said cells, multi-cellular aggregates or tissues to the modified blood clot of claim 58. ### Claim 65 (depends on 58) A kit comprising: (a) a container comprising the modified blood clot of claim 58; and (b) instructions for use of the kit. ### Claim 66 (depends on 65) The kit of claim 65, further comprising a container comprising at least one coagulation activator.